Analgesic and immunomodulatory cannabinoids

Details Analgesic and immunomodulatory cannabinoids Analgesic and immunomodulatory cannabinoids

2005-09-06

2005-09-06

Desai, Rita (Department: 1625)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

C549S388000, C549S390000, C549S391000, C514S455000

Reexamination Certificate

active

06939977

ABSTRACT:
Disclosed are novel compounds represented by the following structural formula:in-line-formulae description="In-line Formulae" end="lead"?R-X-Y;in-line-formulae description="In-line Formulae" end="tail"?and physiologically acceptable salts thereof.R is a tricyclic core of a cannabinoid or substituted cannabinoid.X is a covalent bond, —CH2— or —CHR1—, wherein R1a C1 to C3 substituted or unsubstituted alkyl group.Y is a heterocyclic ring, a substituted heterocyclic ring, a carbocyclic ring, a substituted carbocyclic ring, a fused bicyclic ring system, a substituted fused bicyclic ring system, a bridged bicyclic ring system, a substituted bridged bicyclic ring system, a bridged tricyclic ring system or a substituted bridged tricyclic ring system.Also disclosed is a method of stimulating a CB1 and/or CB2 receptor in a subject. The method comprises administering to the subject a therapeutically effective amount of R-X-Y.

REFERENCES:
patent: 3041343 (1962-06-01), Jucker et al.
patent: 3465024 (1969-09-01), Brownstein et al.
patent: 3573327 (1971-03-01), Miyano
patent: 3577458 (1971-05-01), Brownstein et al.
patent: 3656906 (1972-04-01), Bullock
patent: 3838131 (1974-09-01), Gauthier
patent: 3897306 (1975-07-01), Vidic
patent: 3928598 (1975-12-01), Archer
patent: 3944673 (1976-03-01), Archer
patent: 3953603 (1976-04-01), Archer
patent: 4054582 (1977-10-01), Blanchard et al.
patent: 4087545 (1978-05-01), Archer et al.
patent: 4087546 (1978-05-01), Archer et al.
patent: 4087547 (1978-05-01), Archer et al.
patent: 4088777 (1978-05-01), Archer et al.
patent: 4102902 (1978-07-01), Archer et al.
patent: 4152450 (1979-05-01), Day et al.
patent: 4171315 (1979-10-01), Ryan et al.
patent: 4176233 (1979-11-01), Archer et al.
patent: 4179517 (1979-12-01), Mechoulam et al.
patent: 4188495 (1980-02-01), Althuis et al.
patent: 4208351 (1980-06-01), Archer et al.
patent: 4278603 (1981-07-01), Thakkar et al.
patent: 4282248 (1981-08-01), Mechoulam et al.
patent: 4382943 (1983-05-01), Winter et al.
patent: 4395560 (1983-07-01), Ryan
patent: 4497827 (1985-02-01), Nelson
patent: 4550214 (1985-10-01), Mehta
patent: 4758597 (1988-07-01), Martin et al.
patent: 4812457 (1989-03-01), Narumiya
patent: 4876276 (1989-10-01), Mechoulam et al.
patent: 4885295 (1989-12-01), Bell et al.
patent: 5053548 (1991-10-01), Tanaka et al.
patent: 5068234 (1991-11-01), D'Ambra et al.
patent: 5147876 (1992-09-01), Mizuchi et al.
patent: 5223510 (1993-06-01), Gubin et al.
patent: 5284867 (1994-02-01), Kloog et al.
patent: 5324737 (1994-06-01), D'Ambra et al.
patent: 5434295 (1995-07-01), Mechoulam et al.
patent: 5462960 (1995-10-01), Barth et al.
patent: 5489580 (1996-02-01), Makriyannis et al.
patent: 5521215 (1996-05-01), Mechoulam et al.
patent: 5532237 (1996-07-01), Gallant et al.
patent: 5538993 (1996-07-01), Mechoulam et al.
patent: 5576436 (1996-11-01), McCabe et al.
patent: 5605906 (1997-02-01), Lau
patent: 5607933 (1997-03-01), D'Ambra et al.
patent: 5618955 (1997-04-01), Mechoulam et al.
patent: 5624941 (1997-04-01), Barth et al.
patent: 5635530 (1997-06-01), Mechoulam et al.
patent: 5744459 (1998-04-01), Makriyannis et al.
patent: 5747524 (1998-05-01), Cullinan et al.
patent: 5804601 (1998-09-01), Kato et al.
patent: 5817651 (1998-10-01), D'Ambra et al.
patent: 5925628 (1999-07-01), Lee et al.
patent: 5925768 (1999-07-01), Barth et al.
patent: 5932610 (1999-08-01), Shohami et al.
patent: 5948777 (1999-09-01), Bender et al.
patent: 6013648 (2000-01-01), Rinaldi et al.
patent: 6028084 (2000-02-01), Barth et al.
patent: 6096740 (2000-08-01), Mechoulam
patent: 6127399 (2000-10-01), Yuan
patent: 6166066 (2000-12-01), Makriyannis et al.
patent: 6284788 (2001-09-01), Mittendorf et al.
patent: 6391909 (2002-05-01), Makriyannis et al.
patent: 6579900 (2003-06-01), Makriyannis et al.
patent: 6610737 (2003-08-01), Garzon et al.
patent: 2002/0119972 (2002-08-01), Leftheris et al.
patent: 2003/0120094 (2003-06-01), Makriyannis et al.
patent: 2003/0149082 (2003-08-01), Makriyannis et al.
patent: 2004/0077649 (2004-04-01), Makriyannis et al.
patent: 2004/0077851 (2004-04-01), Makriyannis et al.
patent: 2004/0087590 (2004-05-01), Makriyannis et al.
patent: 0471609 (1993-06-01), None
patent: 0737671 (1996-10-01), None
patent: 0860168 (2001-09-01), None
patent: 2027021 (1980-02-01), None
patent: 57098228 (1982-06-01), None
patent: 2304080 (1990-12-01), None
patent: WO 97/00860 (1997-01-01), None
patent: WO 99/64389 (1999-12-01), None
patent: WO 00/32200 (2000-06-01), None
patent: WO 01/28329 (2001-04-01), None
patent: WO 01/28497 (2001-04-01), None
patent: WO 01/28498 (2001-04-01), None
patent: WO 01/28557 (2001-04-01), None
patent: WO 01/29007 (2001-04-01), None
patent: WO 01/32169 (2001-05-01), None
patent: WO 01/58869 (2001-08-01), None
patent: WO 03/005960 (2003-01-01), None
patent: WO 03/020217 (2003-03-01), None
patent: WO 03/035005 (2003-05-01), None
patent: WO 03/063758 (2003-08-01), None
patent: WO 03/064359 (2003-08-01), None
Abstract from Razdan et al, J. Med. Chem. (1976), 19 (5), 719-21.
Abstract from Belganokar et al, Indian J. Chem. (1975), 13(4), 336-8.
Rompp Chemie Lexikon (1989), 569-579 (in German).
XP-002226467; Pharmacol. Ther. vol. 74, No. 2, pp. 129-180, 1997 (Pharmacology of Cannabinoid CB1 and CB2 Receptors; Roger G. Pertwee.
Abadji V., Lin S., Taha G., Griffin G., Stevenson L.A., Pertwee R.G., Makriyannis A.; “(R)-Methanadamide: a chiral novel anandamide possessing higher potency and metabolic stability”; J. Med. Chem.; 37(12); 1889-1893; 1994; Coden: JMCMAR; ISSN: 0022-2623; XP002040932.
*1* Alo, B.I.; Kandil, A.; Patil, P. A.; Sharp, M. J.; Siddiqul, M. A.; andd Snieckus, V. Sequential Directed Ortho Metalation-Boronic Acid Cross-Coupling Reactions. A general Regiospecific Route to Oxygenerated Dibenzo[b,d]pyran-6-ones Related to Ellagic Acid, J. Org. Chem. 1991, 56, 3763-3768.
***Archer et al; “cannabinoids, synthesis approaches to 9-ketocannabinoids.”; J. Org. Chem.; vol. 42; No. 13; 2277-2284;(1977).
*1* Arnone M., Maruani J., Chaperon P, et al, Selective inhibition of sucrose and ethanol intake by SR141716, an antagonist of central cannabinoid (CB1) receptors, Psychopharmacal, (1997) 132, 104-106, (abstract only).
*1* Beak, P.; and Brown, R.A., The Tertiary Amide as an Effective Director of Ortho Lithiation, J. Org. Chem. 1982, 47, 34-36.
Beltramo M., Stella N., Calignano A., Lin S. Y., Makriyannis A., Piomelli D; “Functional Role Of High-Affinity Anandamide Transport, as Revealed By Selective Inhibition”; Science; vol. 277; 1094-1097; 1997.
Beltramo M., Stella N., Calignano A., Lin S. Y., Makriyannis A., Piomelli D; “Identification and Functional Role of High Affinity Anandamide Transport”; The Neurosciences Institute (1 page).
Berdyshev EV, Cannabinoid receptors and the regulation of immune response. Chem Phys Lipids. Nov. 2000; 108(1-2): 169-90.
Berglund et al; “Structural requirements for arachidonylethanolamide interaction with CB1 and CB2 cannabinoid receptors: . . . ”; Prostanglandins, leukotrienes ands essential fatty acids; 59(2); 111-118; (1998). (abstract only).
Bodnar, V.N., Lozinskii, M.O., Pel'kis, P.S.; “Synthesis fo 2,5-disubstituted 1,3,4-oxadiazoles and 1,4-dihydro-1,2,4,5-tetrazines”; Ukraninskii Khimicheskii Zhurnal (Russian Edition); 48(12); 1308-1311; 1982 (abstract only).
Bracey, M et al, Structural adaptations in a Membrane Enzyme That Terminates Endocannabinoid Signaling. Science 2002; 298(5599): 1793-1796.
*1* Brenneisen R, Pgli A, Elsohly MA, Henn V. Spiess Y: The effect of orally and rectally administered 9—tetrahydrocannabinol on spasticity, a pilot study with 2 patients. Int. J. Clin Pharmacol Ther. (1996) 34:446-452. (abstract only).
*1* ***Brotchie JM: Adjuncts to dopamine replacement a pragmatic approach to reducing the problem of dyskinesia in parkinson's disease. Mov. Disord.(1998)13:871-876.
*1* Brown et al; “Synthesis and hydroboration of (-)-2-phenylapopinene, Comparison of mono(2-phenylapoisopinocampheyl)borane with its 2-methyl and 2-ethyl

Affiliated with

Also associated with

Rating

Analgesic and immunomodulatory cannabinoids does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Analgesic and immunomodulatory cannabinoids, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Analgesic and immunomodulatory cannabinoids will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3408657